The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
According to Amgen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.789. At the end of 2021 the company had a P/E ratio of 21.7.
Year | P/E ratio | Change |
---|---|---|
2021 | 21.7 | 17.02% |
2020 | 18.6 | -0.31% |
2019 | 18.6 | 21.35% |
2018 | 15.3 | -76.8% |
2017 | 66.1 | 366.71% |
2016 | 14.2 | -20.05% |
2015 | 17.7 | -24.46% |
2014 | 23.5 | 38.6% |
2013 | 16.9 | 9.96% |
2012 | 15.4 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 22.4 | 13.44% | ๐บ๐ธ USA |
![]() Pfizer PFE | 7.19 | -63.68% | ๐บ๐ธ USA |
![]() AbbVie ABBV | 23.6 | 19.26% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 50.0 | 152.90% | ๐บ๐ธ USA |
![]() Biogen BIIB | 13.1 | -34.03% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 22.1 | 11.93% | ๐บ๐ธ USA |
![]() Illumina ILMN | -7.93 | -140.07% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 25.1 | 26.67% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 4.43 | -77.59% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.